Bright Minds Biosciences Inc. Common Stock DRUG
Analyst Ratings
- Consensus
- Buy — 6 Buy · 0 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $147.83 (+464.2% upside)
Key Stats
- Today's Range
- $18.90 – $29.94
- 50-Day Range
- $18.90 – $82.50
- 52-Week Range
- $18.90 – $123.75
- Volume
- 1.83 million shs
- Average Volume
- 192K shs
- Market Cap
- $542.33 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.00%
- Days to Cover
- 1.00
About Bright Minds Biosciences Inc. Common Stock
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Related Stocks
Compare head-to-head: DRUG vs AAPL·DRUG vs NVDA·DRUG vs MSFT·DRUG vs GOOGL
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.